A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the ε4 allele

Neurology

Volumn 47, Issue 1, 1996, Pages 196-201

  Mui, S ^a   Briggs, M ^a   Chung, H ^c   Wallace, R B ^b   Gomez Isla, T ^a   Rebeck, G W ^a   Hyman, B T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; ENHANCER REGION; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030054380     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.1.196     Document Type: Article

References (34)

1. Saunders A, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with the late-onset familial and sporadic Alzheimer disease. Neurology 1993;43:1467-1472.
2. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high affinity binding to β/a4 amyloid and increased frequency of type 4 allele in familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
3. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:737.
4. West HL, Rebeck GW, Hyman BT. Frequency of the apolipoprotein E ε2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 1994;175:46-48.
5. Tsai M-S, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994;54: 643-649.
6. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and patho logical correlates of apolipoprotein E ε4 in Alzheimer disease. Ann Neurol 1996;39:62-70.
7. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
8. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 1994;7:180-183.
9. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dosage of apolipoprotein E type 4 allele and the risk for Alzheimer's disease in late onset families. Science 1993;261:921-923.
10. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
11. Ordovas JM, Litwack-Klein L, Wilson PWF, et al. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apoE1 and apoE5 isoforms. J Lipid Res 1986;28:371-380.
12. Rebeck GW, Perls TT, West HL, et al. Reduced apolipoprotein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology 1994;44: 1513-1516.
13. Hyman BT, Gomez-Isla T, Briggs M, et al. Influence of apoE genotype on developing cognitive impairment in the general population. Soc Neurosci 1995;21:1008.
14. Dong LM, Yamamura T, Yamamoto A. Enhanced binding activity of an apolipoprotein E mutant, apoE5, to LDL receptors on human fibroblasts. Biochem Biophys Res Commun 1990; 168:409-414.
15. Lohse P, Brewer B III, Meng MS, et al. Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. J Lipid Res 1992;33:1583-1590.
16. McLean JW, Elshourbagy NA, Chang DJ, Mahley RW, Taylor JM. Human apolipoprotein E mRNA: cDNA cloning and nucleotide sequencing of a new variant. J Biol Chem 1984;259: 6498-6504.
17. Rail S Jr, Weisgraber KH, Innerarity TL, et al. Identification of a new structural variant of human apolipoprotein E, E2 (Lys 146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest 1983;72:1288-1297.
18. Schneider WJ, Kovanen PT, Brown MS, et al. Familial dysbetalipoproteinemia: abnormal binding of mutant apolipoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 1981;68:1075-1085.
19. van den Maagdenberg AM, Weng W, de Bruijn IH, et al. Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no consegregation with severe hyperlipidemia. Am J Hum Genet 1993;52:937-946.
20. Wardell MR, Weisgraber KH, Havekes LM, Rail SC Jr. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem 1989;264:21205-21210.
21. Wardell MR, Rail SC Jr, Schaefer EJ, et al. Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity. J Lipid Res 1991;32:521-528.
22. Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res 1990;31:1503-1511.
23. Betard C, Gee M, Robitaille Y, Cholette AL, Roy P, Gauvreau D. Linkage disequilibrium between a newly identified polymorphism in the apoE enhancer gene region and apoE ε4 allele in Alzheimer patients. In: Roses A, Weisgraber K, Christen Y, eds. Apolipoprotein E and Alzheimer's disease. New York: Springer-Verlag (in press).
24. Paik Y-K, Chang DJ, Reardon CA, Walker MD, Taxman EL, Taylor JM. Identification and characterization of transcriptional regulatory regions associated with expression of the human apolipoprotein E gene. J Biol Chem 1988;263:13340-13349.
25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA group under the auspices of Dept. of HHS Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
26. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114:797-811.
27. Colsher PL, Wallace RB. Longitudinal application of cognitive function measures in a defined population of community-dwelling elders. Ann Epidemiol 1991;1:215-230.
28. White L, Katzman R, Losonczy K, et al. Association of education with incidence of cognitive impairment in three established populations for epidemiologic studies of the elderly. J Clin Epidemiol 1994;47:363-374.
29. Coroni-Huntley J, Brock D, Ostfeld A, et al. National Institute on Aging Established Populations for Epidemiologic Studies of the Elderly: resource book. Bethesda: National Institutes of Health, 1986.
30. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplifications and cleavage with Hha1. J Lipid Res 1990;31:545-548.
31. Saunders AM, Roses AD. Apolipoprotein E4 allele frequency, ischemic cerebrovascular disease, and Alzheimer's disease. Stroke 1993;24:1416.
32. Strittmatter WJ, Saunders AM, Schmechel D, et al. High-avidity binding to β-amyloid and increased frequency of type 4 allele in the late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
33. Dong LM, Wilson C, Wardell MR, et al. Human apolipoprotein E: role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 1994;269:22358-22365.
34. Chartier-Harlin M-C, Parfitt M, Legrain S, et al. Apolipoprotein E, ε4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994;3:569-574.